Showing 7721-7730 of 9757 results for "".
- Epiduo Approved For Patients as Young as 9-Years-Oldhttps://practicaldermatology.com/news/20130219-epiduo_approved_to_treat_acne_in_patients_as_young_as_nine_years_old/2459612/Based on the results of a recent clinical study in pediatric patients, the FDA has approved Epiduo (adapalene 0.1%/BPO 2.5%, Galderma) Gel to treat acne in children as young as nine years old. In the 12-week multicenter, randomized, vehicle-controlled, double-blind study, investigators evaluated the
- FotoFinder Universe App Permits Image Access Via iPadhttps://practicaldermatology.com/news/20130215-fotofinder_universe_app_permits_image_access_via_ipad/2459614/Physicians can access before and after photos from an iPad for viewing, editing, and comparison, using FotoFinder's new Universe app for iPad 2, 3 and 4 and iPad mini. Used in conjunction with the company's mediscope photo documentation suite and Sate
- Red Alert: Rosacea Awareness Month Highlights Social Impact and Warning Signs of Rosaceahttps://practicaldermatology.com/news/20130215-red_alert_rosacea_awareness_month_highlights_social_impact_and_warning_signs_of_rosacea/2459615/According to a new patient survey conducted by the NRS, most rosacea patients feel the negative social impact of their condition regardless of which rosacea subtype they may have. While 61 percent of those with only subtype 1 (erythematotelangiectatic) ro
- Aqua Pharmaceuticals Announces New VP of Saleshttps://practicaldermatology.com/news/20130212-aqua_pharmaceuticals_announces_new_vp_of_sales/2459617/Aqua Pharmaceuticals recently promoted Ted White to Chief Operating Officer (COO). White moves to the new role from his previous position as Vice President of Sales. As COO, White will be responsible for overseeing the daily operation of Aqua and developing business strategies, serving as second-in-
- Survey Data Highlight Expenses and Access-to-Care for Psoriasis Patientshttps://practicaldermatology.com/news/20130208-survey_data_highlight_expenses_and_access-to-care_for_psoriasis_patients/2459618/New findings from the National Psoriasis Foundation (NPF) indicate that patients with psoriasis and psoriatic arthritis patients spend more than $2,500 per year in out-of-pocket costs for their disease. In an analysis of eight years of data to determine access-to-care issues and out-of-pocket costs
- Merz Aesthetics Appoints New VPhttps://practicaldermatology.com/news/20130206-merz_aesthetics_appoints_new_vp/2459620/Jim Hartman has been appointed Vice President of Merz Aesthetics, Inc. Business Unit, which includes Xeomin, Radiesse, and Belotero Balance. Prior to joining Merz, Hartman was the Vice President, Global Marketing & Business Development, at Obagi Medical Products, a provider of topical skincare treat
- Aesyntix Partners With Sentéhttps://practicaldermatology.com/news/20130125-aesyntix_partners_with_sent/2459626/Aesyntix Physician Network (APN), a group purchasing organization and subsidiary of Aesyntix Health, Inc., entered into an agreement with Senté, Inc., a privately held cosmeceutical company that develops differentiated medical skincare pro
- Provectus Pharmaceuticals to Present on PV-10 at AACRhttps://practicaldermatology.com/news/20130123-provectus_pharmaceuticals_to_present_on_pv-10_at_aacr/2459631/Provectus Pharmaceuticals, Inc. will present data on PV-10 in a poster presentation at the American Association for Cancer Research Annual Meeting in Washington, DC. The PV-10 combination therapy poster, based upon an abstract entitled "Combination o
- Allergan, Inc. to Acquire MAP Pharmaceuticals, Inc.https://practicaldermatology.com/news/20130123-allergan_inc_to_acquire_map_pharmaceuticals_inc/2459632/Allergan, Inc. and MAP Pharmaceuticals, Inc. entered into a definitive merger agreement whereby Allergan will acquire 100 percent of the shares of MAP Pharmaceuticals for a price of $25.00 pe
- BOTOX Receives FDA Approval for Overactive Bladderhttps://practicaldermatology.com/news/20130121-botox_receives_fda_approval_for_overactive_bladder/2459633/The US FDA just approved BOTOX (onabotulinumtoxinA) from Allergan, Inc. for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency in adults who have had an inadequate response to or are intol